Drug monographs

Avelumab and ribociclib

James Waddell, Dominic A. Solimando

Research output: Contribution to journalArticle

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Original languageEnglish (US)
Pages (from-to)459-463
Number of pages5
JournalHospital Pharmacy
Volume52
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Oncology
Pharmacists
Pharmaceutical Services
Chemotherapy
Poisons
Highway systems
Postal Service
Pharmaceutical Preparations
Antineoplastic Agents
Drug Therapy
Neoplasms
avelumab
ribociclib
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)

Cite this

Drug monographs : Avelumab and ribociclib. / Waddell, James; Solimando, Dominic A.

In: Hospital Pharmacy, Vol. 52, No. 7, 01.07.2017, p. 459-463.

Research output: Contribution to journalArticle

Waddell, James ; Solimando, Dominic A. / Drug monographs : Avelumab and ribociclib. In: Hospital Pharmacy. 2017 ; Vol. 52, No. 7. pp. 459-463.
@article{52e9e47a6c924154b763866a4cbe1a36,
title = "Drug monographs: Avelumab and ribociclib",
abstract = "The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.",
author = "James Waddell and Solimando, {Dominic A.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1177/0018578717719183",
language = "English (US)",
volume = "52",
pages = "459--463",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "7",

}

TY - JOUR

T1 - Drug monographs

T2 - Avelumab and ribociclib

AU - Waddell, James

AU - Solimando, Dominic A.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

AB - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

UR - http://www.scopus.com/inward/record.url?scp=85032442626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032442626&partnerID=8YFLogxK

U2 - 10.1177/0018578717719183

DO - 10.1177/0018578717719183

M3 - Article

VL - 52

SP - 459

EP - 463

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 7

ER -